Evidence review
Does Your Employer's Health Plan Cover a GLP-1? How to Find Out Today
Coverage odds rise sharply with employer size. How to read your own plan documents, what to ask, and what to do if the answer is no.
On this page
The short answer
Your odds depend less on which drug you want than on how many people your employer employs. In KFF's 2025 employer survey, among firms offering health benefits with 200 or more workers, 16% of firms with 200 to 999 workers covered GLP-1 agonists used primarily for weight loss — against 30% at firms with 1,000 to 4,999 workers and 43% at firms with 5,000 or more1.
That is the single most useful thing nobody tells a working mother before she spends an afternoon on hold. It also means the answer is knowable in about ten minutes, from documents your employer already owes you.
Coverage odds by employer size
| Firm size (offering health benefits) | Share covering GLP-1 agonists primarily for weight loss, 2025 |
|---|---|
| 200–999 workers | 16% |
| 1,000–4,999 workers | 30% |
| 5,000+ workers | 43% (up from 28% the prior year) |
Two more numbers from the same survey change what you should do with this. Among firms that do cover these drugs for weight loss, 34% require the enrollee to meet with a dietitian, case manager, or therapist, or to take part in a lifestyle program, in order to get the coverage1. And among large firms that do not cover them, only 1% said they were "very likely" to start within the next twelve months; 67% said they were not likely1.
Read that second figure carefully, because it settles a real decision. If your plan excludes weight-loss GLP-1s this year, waiting for open enrollment to fix it is not a plan. It is a 1-in-100 bet.
Step one: find out whether your plan is self-funded
This sounds like trivia and it is not. Sixty-seven percent of covered workers — and 80% of those at firms with 200 or more workers — are in plans that are self-funded, meaning the employer pays claims out of its own money and simply hires an insurance company to administer them1.
It matters because federal law treats those plans differently. Under ERISA, federal rules supersede state laws that relate to an employee benefit plan, and a self-funded plan may not be deemed an insurance company for the purpose of any state law regulating insurers2. In plain terms: state insurance mandates, and state patient-protection laws you may have read about, generally do not reach a self-funded employer plan. The name on your card is the administrator. The decision-maker is your employer.
How to tell, without asking anyone: open your Summary Plan Description and look for the sentence naming who pays benefits. A self-funded plan says benefits are paid from the employer's general assets or a plan trust, with a named company acting only as claims administrator. An insured plan names an insurance policy.
Step two: three documents, in this order
- The Summary of Benefits and Coverage. Short, standardized, and legally required to be given to you. Find the prescription drug row and the exclusions section.
- The exclusions list. This is the one people skip. Some plans list every GLP-1 on the formulary and separately exclude "anti-obesity medications" or "drugs for weight loss" as a benefit category. The drug list can say yes while the benefit says no.
- The formulary, plus its prior authorization criteria document. The formulary tells you tier. The criteria document — often a separate PDF — tells you the BMI threshold, the documented-attempt requirement, and how long approval lasts before you have to do it again.
If your plan is one of the 34% that attaches a lifestyle-program condition, it will be in that criteria document, not in the drug list1. Finding it early is worth a month, because those programs have enrollment steps of their own.
Step three: the phone script
Four questions, in this order, to the member number on your card. Write the answers down with the date and the representative's name.
- Is [drug name] covered under my pharmacy benefit for weight management — not for diabetes?
- Is there a separate exclusion for anti-obesity medications in my plan?
- What are the prior authorization criteria, and can you send me the criteria document?
- If approved, what is my cost share — a flat copay, or coinsurance as a percentage?
Question two is the one that saves you the afternoon. A representative reading the formulary will happily confirm the drug is "on the list" while the benefit category is excluded four screens away.
The diagnosis on the prescription is doing the work
Insurers key coverage to the FDA-approved use, not to the molecule. Wegovy's label carries indications for reducing major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, for weight reduction and long-term maintenance, and for noncirrhotic MASH with moderate to advanced fibrosis3. Zepbound's label covers weight reduction and long-term maintenance in adults with obesity or overweight with a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity4.
That is why a plan can pay for one prescription and refuse a chemically identical one: the difference is the indication being treated. Our guide to what happens when your plan covers one GLP-1 but not the other walks the switch decision, and does insurance cover a GLP-1 for weight loss covers the Medicaid and Medicare rules that sit outside the employer world.
If the answer is no
Then you are choosing between two real paths rather than one dead end.
- Fight the specific denial. If your plan covers the category but denied you, the problem is usually documentation. Start with prior authorization: getting approved and appealing a denial, then use our denial-reason appeal letter templates.
- Pay cash and reclaim what you can. A cash-pay program is often cheaper than a covered brand after coinsurance, and the tax-advantaged route is real money — see the letter of medical necessity your FSA administrator wants, then the shortlist on our cheapest GLP-1 board or the board built for women.
The decisive takeaway
Coverage for a weight-loss GLP-1 is an employer purchasing decision before it is a medical one, it tracks employer size, and it is written down in three documents you can pull today. Check the exclusions list before you believe the formulary, find out whether your plan is self-funded before you rely on any state rule, and if the answer is no, move to the cash lane rather than waiting on a 1% chance your employer changes its mind. Some links here earn us a referral fee, which never changes the ranking.
Frequently asked questions
How do I know if my insurance covers obesity treatment?
Pull three documents: the Summary of Benefits and Coverage, the plan's exclusions list, and the formulary with its prior authorization criteria. Check the exclusions list specifically for an 'anti-obesity medication' or 'weight loss drug' carve-out, because a plan can list the drug on its formulary and still exclude the benefit category. Then call the member number and ask whether the drug is covered for weight management specifically, not for diabetes.
Does employer size really change my odds?
Substantially. In KFF's 2025 employer survey, 16% of firms with 200 to 999 workers covered GLP-1 agonists used primarily for weight loss, versus 30% at 1,000 to 4,999 workers and 43% at 5,000 or more. Coverage at the largest firms rose from 28% the prior year, so the gap between small and large employers is widening rather than closing.
My plan excludes it. Should I wait for open enrollment?
Probably not. Among large firms that do not cover GLP-1 agonists for weight loss, only 1% told KFF they were 'very likely' to begin covering them within the next twelve months, and 67% said they were not likely. Waiting a full plan year for a change that is unlikely to come costs you the year. Price the cash lane in parallel rather than instead.
Where this leaves you
References
- KFF (Kaiser Family Foundation) (2025). Employer Health Benefits Survey — 2025 Annual Survey, Summary of Findings. KFF. https://files.kff.org/attachment/Employer-Health-Benefits-Survey-2025-Annual-Survey-Summary-of-Findings.pdf
- United States Code (2026). 29 U.S.C. 1144 — Other laws (ERISA preemption, savings and deemer clauses). Office of the Law Revision Counsel, U.S. House of Representatives. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title29-section1144&num=0&edition=prelim
- Novo Nordisk (FDA label via DailyMed) (2026). WEGOVY (semaglutide) — Indications and Usage. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Eli Lilly (FDA label via DailyMed) (2026). ZEPBOUND (tirzepatide) — Indications and Usage. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
Read this as information, not instructions. WorkingMomRx is educational and never a diagnosis, a treatment plan, or a reason to start or stop a medication. A GLP-1 is a clinical decision — run it past a licensed clinician who knows your history before you act on anything here.
Continue reading
Who Actually Decides Whether Your Plan Pays for a GLP-1
Your insurer's name is on the card, but a pharmacy benefit manager writes the formulary. How to find yours and get your own number.
ReadYour Plan Covers One GLP-1 and Not the Other: What Now
Why plans pay for one weight-loss GLP-1 and refuse another, what switching actually costs you in weeks, and how to request an exception.
ReadGLP-1 Denial Appeal Letters: Templates by Reason for Denial
Copy-and-send appeal paragraphs for the five most common GLP-1 denial reasons, plus the federal deadlines that govern your appeal.
Read